IDH2 and acute myeloid leukemia: These findings may suggest that in patients affected by IDH-mutated AML, treatment with the specific inhibitor leads to a phase of differentiation of leukemic cells and clonal trilineage hemopoietic recovery with peripheral blood count improvement, which occurs in clinically responding patients, who also show progressive transfusion independence, as reported in seminal clinical studies [26,27,41].